The LGPLVEQGR peptide corresponding to APOE in patients with early-stage CRC (0.58-fold, p < 0.0001) and late-stage CRC (0.68-fold, p < 0.0001) was significantly lower than that of the HC group (Figure 2C). This evidence concerns the gene APOE and colorectal carcinoma.